Lupin (Large Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Lupin Limited |
|||
|
Price: ₹2,104.25 (-1.24%) | ||
| 52 Week Low: ₹1,414.00 52 Week High: ₹2,402.90 |
|||
| Market Capital: 91,962.06 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Lupin Share Price Target For 2025
- 1.1.1: Lupin Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Lupin Share Price Target For 2026
- 1.2.1: Lupin Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Lupin Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Lupin Brief Company Overview
- 4: Lupin Financial Performance
- 4.0.1: Is Lupin A Good Buy For Long Term?
Lupin, a Large Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 201.0% returns in 5-year showing 12.6% quarterly revenue growth with 12.2% profit margin, making it a potential Multibagger.
To predict the Lupin's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Lupin Share Price Target For 2025
The line chart displays the monthly closing prices of Lupin with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Lupin shares in 2025, see the table below.
Lupin Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 2296.8 (+9.15%) | Price Action: 31 Dec 2024 Low |
| 2025 Target 2 | 2272.0 (+7.97%) | Price Action: 03 Sep 2024 High |
| 2025 Target 1 | 2247.3 (+6.79%) | Price Action: 06 Sep 2024 Low |
| Current Price | 2104.25 | Lupin's share price as of 21 Jan 2025 |
| Stop Loss 1 | 2041.85 (-2.97%) | Price Action: 27 Nov 2024 High |
| Stop Loss 2 | 2021.0 (-3.96%) | Price Action: 28 Nov 2024 High |
| Stop Loss 3 | 2000.55 (-4.93%) | Price Action: 27 Nov 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Lupin is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹2144.84 serves as the nearest technical reference point.
Historical Returns: 3-month: -3.78% | 6-month: +10.06% | 1-year: +40.4%
Lupin Share Price Target For 2026
The line chart displays the monthly closing prices of Lupin with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Lupin shares in 2026, see the table below.
Lupin Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 3355.64 (+59.46%) | Price Action: Chart |
| 2026 Target 2 | 3293.07 (+56.49%) | Fibonacci Extension Level 150.00% |
| 2026 Target 1 | 3259.68 (+54.9%) | Fibonacci Extension Level 64.90% |
| Current Price | 2104.25 | Lupin's share price as of 21 Jan 2025 |
| Stop Loss 1 | 1839.81 (-12.57%) | Price Action: Nov 2015 High |
| Stop Loss 2 | 1820.97 (-13.47%) | Price Action: 11 Jul 2024 High |
| Stop Loss 3 | 1799.56 (-14.48%) | Price Action: 11 Jul 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Lupin is currently trading at 69.8% of its 52-week range (₹1414 - ₹2402.9).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +40.4% | 3-year: +135.19% | 5-year: +200.97%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Lupin Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹2,104.25 | ||
| 2025 | ₹2,795.31 | +32.84% | ₹2,837.24 |
| 2026 | ₹3,614.37 | +29.3% | ₹3,668.59 |
| 2027 | ₹5,004.77 | +38.46% | ₹5,079.84 |
| 2028 | ₹6,913.09 | +38.13% | ₹7,016.79 |
| 2029 | ₹8,735.73 | +26.36% | ₹8,866.77 |
| 2030 | ₹11,217.29 | +28.4% | ₹11,385.55 |
| 2031 | ₹13,214.65 | +17.8% | ₹13,412.87 |
| 2032 | ₹14,827.57 | +12.2% | ₹15,049.98 |
| 2033 | ₹18,322.19 | +23.56% | ₹18,597.02 |
| 2034 | ₹23,706.15 | +29.38% | ₹24,061.74 |
| 2035 | ₹29,160.38 | +23% | ₹29,597.79 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Lupin Brief Company Overview
Lupin Limited: A Pharmaceutical Giant Established in 1968, Lupin Limited is a renowned pharmaceutical company headquartered in Mumbai, India. Key Products and Services: Branded and generic formulations Biotechnology products Active pharmaceutical ingredients...
(APIs) Biosimilars Over-the-counter products Drug discovery and development Bio clinical research Market Presence: Lupin operates globally through a network of labs, LupiMitra collection centers, and pick-up points. Reputation: Lupin Limited has earned a strong reputation in the pharmaceutical industry for its commitment to: Innovation and research Quality and affordability Patient care Diversity: Lupin's diverse product range caters to various therapeutic areas, including: Cardiovascular Diabetology Asthma Gastrointestinal Anti-infective Respiratory Women's health Anti-tuberculosis Oncology Immunology Metabolic disordersLupin Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 91,962.06 Crore | Market valuation of Lupin's shares. |
| Revenue (TTM) | 21,431.25 Crore | Total revenue generated by Lupin over the past twelve months. |
| Net Income (TTM) | +2,626.48 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +19.55% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +12.25% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+12.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+74.09% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
21.89 | Company's total debt divided by total shareholder equity. |
| Total Debt | 3,442.49 Crore | Sum of Lupin's current & long-term financial obligations. |
| Total Cash | 2,912.31 Crore | Total amount of liquid funds available to Lupin. |
| Beta | 0.58 | Beta is less than 1 indicating that the Lupin's price is less volatile than the market. |
Is Lupin A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
